Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 001 - Agastiya Biotech

Next Previous
X
Search
Drug Profile

AB 001 - Agastiya Biotech

Alternative Names: AB-01; AB01-Agastiya Biotech

Latest Information Update: 10 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agastiya Biotech
  • Developer Agastiya Biotech; Vopec Pharmaceuticals
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Programmed cell death-1 ligand-1 inhibitors; Ras signal transduction pathway inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Pancreatic cancer

Most Recent Events

  • 10 Apr 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) (PO) prior to April 2024
  • 10 Apr 2024 Interim safety, efficacy, pharmacodynamics data from phase I trial in Solid tumours released by Agastiya Biotech
  • 08 Apr 2024 AB 001 - Agastiya Biotech receives Orphan Drug status for Glioblastoma in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top